US Home - VANCO READY™

VANCO READY™
Vancomycin
Injection Premix

Click here to see full
Prescribing Information
including BOXED WARNING.

VANCO READY™ The only ready-to-use vancomycin that's truly ready to infuse1 

VANCO READY™ requires no thawing, compounding, or activating: 

  • Room temperature stable
  • 16-month shelf life in overwrap
  • Fits in automated dispensing units

All the doses you need

VANCO READY™ premix is
available as 7 different doses 
from 500 mg to 2 g.1


Time to first dose

When it comes to sepsis, VANCO READY™ could help reduce antimicrobial lead time.

Learn More

Risk mitigation

VANCO READY™ may help reduce the potential risk for errors associated with compounding drugs.

Learn More

Standardized across your institution

VANCO READY™ streamlines complex delivery systems.

Learn More

Preferred by US institutions

VANCO READY™ is currently utilized in over 1,800 institutions nationwide.

Learn More

GET FULLY READY

VANCO READY™ is available in
7 different dose amounts to cover most
of your patients' vancomycin needs.

Order VANCO READY™ NOW
INDICATIONS AND USAGE
Vancomycin Injection, USP is a glycopeptide antibacterial indicated in adult and pediatric patients (1 month and older) for the treatment of
  • Septicemia (1.1)
  • Infective Endocarditis (1.2)
  • Skin and Skin Structure Infections (1.3)
  • Bone Infections (1.4)
  • Lower Respiratory Tract Infections (1.5)

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Vancomycin Injection, USP and other antibacterial drugs, Vancomycin Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. (1.6)

IMPORTANT SAFETY INFORMATION

WARNING: RISK OF EMBRYO-FETAL TOXICITY DUE TO EXCIPIENTS
See full prescribing information for complete boxed warning. This formulation of Vancomycin Injection, USP is not recommended for use during pregnancy because it contains the excipients polyethylene glycol (PEG 400) and N-acetyl D-alanine (NADA), which caused fetal malformations in animal reproduction studies. If use of vancomycin is needed during pregnancy, use other available formulations of vancomycin. (5.1, 8.1)

DOSAGE AND ADMINISTRATION
  • Use this formulation of Vancomycin Injection, USP only in patients who require the entire (500 mg, 750 mg, 1 g, 1.25 g, 1.5 g, 1.75 g or 2 g) dose and not any fraction thereof. (2.1) 
  • For intravenous use only. Do Not administer orally 
  • Administer Vancomycin Injection, USP by intravenous infusion over 60 minutes or greater to reduce the risk of infusion reactions (2.1)
  • Adult Patients: 2 g divided either as 0.5 grams (g) every 6 hours or 1 g every 12 hours (2.2)
  • Pediatric Patients (1 Month and Older): 10 mg/kg per dose given every 6 hours (2.3)
  • Patients with Renal Impairment: See full prescribing information for recommended doses in patients with renal impairment (2.4)
  • See full prescribing information for further important administration and preparation instructions (2.1, 2.5)

DOSAGE FORMS AND STRENGTHS
Vancomycin Injection, USP: Single-dose flexible bags containing 500 mg vancomycin in 100 mL, 750 mg vancomycin in 150 mL, 1 g vancomycin in 200 mL, 1.25 g vancomycin in 250 mL, 1.5 g vancomycin in 300 mL, 1.75 g vancomycin in 350 mL and 2 g vancomycin in 400 mL of liquid. (3)
CONTRAINDICATIONS
  • Hypersensitivity to vancomycin (4)

WARNINGS AND PRECAUTIONS
  • Infusion Reactions: Hypotension, including shock and cardiac arrest, wheezing, dyspnea, urticaria, muscular and chest pain and “red man syndrome” which manifests as pruritus and erythema that involves the face, neck and upper torso may occur with rapid intravenous administration. To reduce the risk of infusion reactions, administer Vancomycin Injection, USP over a period of 60 minutes or greater and also prior to intravenous anesthetic agents. (2.1, 5.2)
  • Nephrotoxicity: Systemic vancomycin exposure may result in acute kidney injury (AKI) including acute renal failure, mainly due to interstitial nephritis or less commonly acute tubular necrosis. Monitor serum vancomycin concentrations and renal function. (5.3)
  • Ototoxicity: Ototoxicity has occurred in patients receiving vancomycin. Monitor for signs and symptoms of ototoxicity during therapy. Monitor serum vancomycin concentrations and renal function. Assessment of auditory function may be appropriate in some instances. (5.4)
  • Clostridium Difficile-Associated Diarrhea: Evaluate patients if diarrhea occurs. (5.5)
  • • Neutropenia: Periodically monitor leukocyte count. (5.7)
  • • Phlebitis: To reduce the risk of local irritation and phlebitis administer Vancomycin Injection, USP by a secure intravenous route of administration. (5.8)
  • Development of Drug-Resistant Bacteria: Prescribing Vancomycin Injection, USP in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug resistant bacteria. (5.9)

ADVERSE REACTIONS
The common adverse reactions are anaphylaxis, “red man syndrome”, acute kidney injury, hearing loss, neutropenia. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Xellia Pharmaceuticals USA, LLC at 1-833-295-6953 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS
  • Anesthetic Agents: Concomitant administration of vancomycin and anesthetic agents has been associated with erythema and histamine-like flushing. (2.1, 7.1)
  • Piperacillin/Tazobactam: Increased incidence of acute kidney injury in patients receiving concomitant piperacillin/tazobactam and vancomycin as compared to vancomycin alone. Monitor kidney function in patients. (7.2)
Download Complete Prescribing Information

Reference:

1. VANCO READY™ Prescribing Information. Xellia Pharmaceuticals; 2020.